Carl A Nunziato, MD | |
3d Medical Battalion, Unit 38445, Fpo, AP 96373-8445 | |
(315) 645-4197 | |
Not Available |
Full Name | Carl A Nunziato |
---|---|
Gender | Male |
Speciality | Orthopaedic Surgery |
Location | 3d Medical Battalion, Fpo, Armed Forces Pacific |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1750815320 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207X00000X | Orthopaedic Surgery | R9410 (Texas) | Primary |
Entity Name | Concord Medical Group Of Texas Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20141007002567 |
News Archive
Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), one of Japan's leading biopharmaceutical companies, announced today that the two companies have entered into a research collaboration and license agreement for the research, development and commercialization of drug delivery systems and DsiRNA pharmaceuticals for therapeutic targets in oncology.
Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, and Handok Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical company, today announced a collaboration for the development and commercialization of apaziquone in South Korea. Apaziquone is an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.
Cancer patients fear the possibility that one day their cells might start rendering many different chemotherapy regimens ineffective. This phenomenon, called multidrug resistance, leads to tumors that defy treatment.
Adults with severe heart failure see almost three times as many Medicare providers each year compared to a typical beneficiary, according to research presented at the American Heart Association's Scientific Sessions 2008.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Carl A Nunziato, MD Psc 557 Box 416, Fpo, AP 96379-0005 Ph: (310) 560-6609 | Carl A Nunziato, MD 3d Medical Battalion, Unit 38445, Fpo, AP 96373-8445 Ph: (315) 645-4197 |
News Archive
Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), one of Japan's leading biopharmaceutical companies, announced today that the two companies have entered into a research collaboration and license agreement for the research, development and commercialization of drug delivery systems and DsiRNA pharmaceuticals for therapeutic targets in oncology.
Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, and Handok Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical company, today announced a collaboration for the development and commercialization of apaziquone in South Korea. Apaziquone is an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.
Cancer patients fear the possibility that one day their cells might start rendering many different chemotherapy regimens ineffective. This phenomenon, called multidrug resistance, leads to tumors that defy treatment.
Adults with severe heart failure see almost three times as many Medicare providers each year compared to a typical beneficiary, according to research presented at the American Heart Association's Scientific Sessions 2008.
› Verified 2 days ago
Dr. James Michael Harrison, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 676 Futenma, Fpo, AP 96379 Phone: 098-971-9355 | |
Dr. Joshua Paul Garland, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: Psc 475 Box 1, Fpo, AP 96350 Phone: 315-243-5868 | |
Dr. Thomas Kelsey, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: Psc 482, Fpo, AP 96362 Phone: 098-971-7351 | |
Dr. Frederic Sylvia, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: Psc 482 Box 217, Fpo, AP 96362 Phone: 011-816-117437297 | |
Dr. Jason Howard Rockwood, D.O. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: Psc 475 Box 1, Fpo, AP 96350 Phone: 046-816-7144 |